JP Morgan Chase’s Calidi Biotherapeutics CLDI Stock Holding History

JP Morgan Chase’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$14	–	7475
2025 Q3	$14	Buy	+1	New	+$68	﹤0.01%	7301
2025 Q2	–	Hold	0	–	–	–	6969

Other funds holding CLDI

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase's CLDI Position: Q4 2025 in Review

JP Morgan Chase sold out of Calidi Biotherapeutics (CLDI) in Q4 2025, closing a stake of 1 share — an estimated $14 sold.

JP Morgan Chase first reported a position in CLDI in Q3 2025 and held it in 1 quarter. The position peaked at $14 in Q3 2025. 25 funds tracked by Wall St. Rank hold CLDI as of Q4 2025.

JP Morgan Chase reported no remaining Calidi Biotherapeutics position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 1 Calidi Biotherapeutics share in Q4 2025, an estimated $14.
JP Morgan Chase first reported a position in Calidi Biotherapeutics in Q3 2025 and held it in 1 quarter.
JP Morgan Chase's Calidi Biotherapeutics position peaked at $14 in Q3 2025.
25 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.